Evidence map›Paper›PMID 38395940›Full record

ArticleAddiction science & clinical practice2024

"Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.

Brenda Kamusiime, Kristin Beima-Sofie, Nok Chhun, Alisaati Nalumansi, Grace Kakoola Nalukwago, Vicent Kasiita, Chris Collins Twesige, Ritah Kansiime, Timothy R Muwonge, Peter Kyambadde and 6 more

Open access · goldAbstract read
In one paragraph

Article in Addiction science & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Brenda Kamusiime *Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Kristin Beima-Sofie *Department of Global Health, University of Washington, 3980 15th Ave NE, Box 351620, Seattle, WA, 98195, USA. beimak@uw.edu.ORCID 0000-0002-3408-7410
Nok ChhunDepartment of Global Health, University of Washington, 3980 15th Ave NE, Box 351620, Seattle, WA, 98195, USA.
Alisaati NalumansiInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Grace Kakoola NalukwagoInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Vicent KasiitaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Chris Collins TwesigeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Ritah KansiimeMost-At-Risk Populations Initiative (MARPI), National STI Control Unit, Kampala, Uganda.
Timothy R MuwongeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Peter KyambaddeMost-At-Risk Populations Initiative (MARPI), National STI Control Unit, Kampala, Uganda.
Herbert KadamaMinistry of Health, Kampala, Uganda.
Peter MudiopeMinistry of Health, Kampala, Uganda.
Sara GlickDepartment of Medicine, University of Washington, Seattle, USA.
Barrot LambdinDepartment of Global Health, University of Washington, 3980 15th Ave NE, Box 351620, Seattle, WA, 98195, USA.
Andrew Mujugira *Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Renee Heffron *Department of Medicine, University of Alabama at Birmingham, Birmingham, USA.
Infectious Diseases Institute · UGUniversity of Washington · USMinistry of Health · UGRTI International · USUniversity of Alabama at Birmingham · US

Funding

Implementation science research on PrEP delivery and costing within MAT andNSP services for PWUD in UgandaR01DA051796 · NIDA · UNIVERSITY OF WASHINGTON · PI HEFFRON, RENEE A. · 2020 to 2024
$3.4M
NIDA NIH HHS R01 DA051796NIH HHS R01DA051796
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) are at increased risk of HIV acquisition and often encounter barriers to accessing healthcare services. Uganda has high HIV prevalence among PWID and lacks integrated pre-exposure prophylaxis (PrEP) and harm reduction services. Understanding PWID experiences accessing and using harm reduction services and PrEP will inform strategies to optimize integration that align with PWID needs and priorities.

methodsBetween May 2021 and March 2023, we conducted semi-structured interviews with PWID in Kampala, Uganda. We recruited participants with and without previous experience accessing harm reduction services and/or PrEP using purposive and snowball sampling. Interviews were audio recorded, translated, and transcribed. We used thematic analysis to characterize motivations for uptake of harm reduction and HIV prevention services, and strategies to optimize delivery of needle and syringe programs (NSP), medications for opioid use disorder (MOUD), and PrEP.

resultsWe conducted interviews with 41 PWID. Most participants were relatively aware of their personal HIV risk and accurately identified situations that increased risk, including sharing needles and engaging in transactional sex. Despite risk awareness, participants described engaging in known HIV risk behaviors to satisfy immediate drug use needs. All reported knowledge of harm reduction services, especially distribution of sterile needles and syringes, and many reported having experience with MOUD. Participants who had accessed MOUD followed two primary trajectories; limited resources and relationships with other PWID caused them to discontinue treatment while desire to regain something they believed was lost to their drug use motivated them to continue. Overall, PrEP knowledge among participants was limited and few reported ever taking PrEP. However, participants supported integrating PrEP into harm reduction service delivery and advocated for changes in how these services are accessed. Stigma experienced in healthcare facilities and challenges acquiring money for transportation presented barriers to accessing current facility-based harm reduction and HIV prevention services.

conclusionsMeeting the HIV prevention needs of PWID in Uganda will require lowering barriers to access, including integrated delivery of PrEP and harm reduction services and bringing services directly to communities. Additional training in providing patient-centered care for healthcare providers may improve uptake of facility-based services.

Indexed as

Acquired Immunodeficiency SyndromeDrug UsersHIV InfectionsOpioid-Related DisordersSubstance Abuse, IntravenousHarm ReductionHumansPharmaceutical PreparationsUgandaPharmaceutical PreparationsHarm reduction servicesHIV preventionPeople who inject drugs (PWID)People who use drugs (PWUD)Pre-exposure prophylaxis (PrEP)

Identifiers

PMID38395940
PMCPMC10893723
OpenAlexW4392093168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.